Comparative Pharmacology
Head-to-head clinical analysis: ASACOL HD versus CANASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASACOL HD versus CANASA.
ASACOL HD vs CANASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) derivative that acts locally in the colon to reduce inflammation by inhibiting prostaglandin production and leukotriene synthesis, likely through scavenging free radicals and blocking cytokine release.
Mesalamine (5-aminosalicylic acid) is an anti-inflammatory agent that inhibits prostaglandin and leukotriene synthesis, scavenges reactive oxygen species, and inhibits cytokine production and nuclear factor-kappa B (NF-κB) activation in colonic mucosa.
2 tablets (1600 mg) once daily with or without food.
Mesalamine 1000 mg rectally once daily at bedtime, or 500 mg rectally twice daily (morning and evening). Administered as suppository for ulcerative colitis.
None Documented
None Documented
Terminal elimination half-life is 5-10 hours for 5-ASA and 5-10 hours for acetyl-5-ASA; clinically, it supports twice-daily dosing.
Terminal elimination half-life of mesalamine is approximately 0.5-2 hours; however, the N-acetyl metabolite has a half-life of 5-10 hours. Due to the sustained-release formulation, clinical effects persist beyond the plasma half-life.
Primarily renal excretion of acetyl-5-ASA (about 80% of absorbed dose) and unchanged 5-ASA; minor fecal elimination (<20%).
Renal (approximately 20-30% as unchanged drug and metabolites, primarily N-acetyl-5-aminosalicylic acid); biliary/fecal (the remainder, with extensive enterohepatic circulation).
Category C
Category C
Aminosalicylate
Aminosalicylate